Biotechnology Venture Investing and Neurodegenerative Medicine: Promise of New Approaches to Cure an Ailing Model
Requires Subscription or Fee PDF


Drug Discovery
Drug development


Neurodegenerative diseases are one of the leading public health challenges of the next 50 years. Pharmaceutical therapies have traditionally targeted the later stages of neurodegenerative diseases; however, this strategy - as the recent failures of clinical trials for Alzheimer’s drugs have highlighted - has been unsuccessful. Venture capital has underperformed as well during this time, as many new companies have been unable to maintain growth once they reach the public market and have produced less than desirable returns. As a result, venture capitalists have opted for later-stage financing. Nevertheless, new technologies are being developed to answer the question of how to best address neurodegeneration. New tools of detection will allow for much earlier diagnosis and a much greater chance of discovering and applying effective treatments. Realizing that genetic knowledge is insufficient to produce innovative treatments for neurodegenerative diseases, scientists have begun to apply the genetic knowledge attained towards a future of individualized treatments. As these new tools of detection converge with an increased ability to create very precise individual solutions, the risk of successful future investments should come down and provide the potential for outsized returns that have traditionally governed the venture capital financial model.
Requires Subscription or Fee PDF


Alzheimer’s Association. (2012) 2012 Alzheimer’s disease facts and figures. Alzheimer’s and Dementia: The Journal of the Alzheimer’s Association 8(2): 131-168

Harvard NeuroDiscovery Center. (2012) The challenge of neurodegenerative diseases., accessed 7 June 2012.

U.S. Department of Health and Human Services (2012) Recommendations of the Public Members of the Advisory Council on Alzheimer’s research, care and services., accessed 7 June 2012.

Medivation (2010) Pfizer and Medivation Announce Results from Two Phase 3 Studies in Dimebon (latrepirdine*) Alzheimer’s Disease Clinical Development Program., accessed 7 June 2012.

Alzheimer’s Research Forum (2010) Dimebon Dissapoints in Phase 3 Trial. Alzheimer’s Research Forum., accessed 7 June 2012.

Rupert Shepherd (2012) Medivation and Pfizer Axe their new Alzheimer’s drug Dimebon. Medical News Today., accessed 7 June 2012.

Alzheimer’s Research Forum (2012) CONCERT Trial of Dimebon Falls Flat. Alzheimer’s Research Forum., accessed 7 June 2012.

Ryan Finn (2012) Biotechnology Funding Hits 4-Year High While Startups Seek New Investments. Bloomberg., accessed 7 June 2012.

PwC (2012) Mixed MomentumPwC Health., accessed 7 June 2012.

National Venture Capital Association (2012) VC Investments Q1 ’12-MoneyTree – National Data. National Venture Capital Association

Bruce Booth (2011) A Look Back at 2010-2011 Class of Biotech IPOs: Not Dead Yet. LifeSciVC, accessed 7 June 2012.

Daniel S. Levine (2011) Biotech IPO Class of 2011 Takes Drubbing. Seeking Alphaα., accessed 7 June 2012.

Accelerate Brain Cancer Cure (2013) Our Mission and Focus: to invest in research aimed at finding the fastest possible route to a cure., accessed 7 July 2013

Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision. (2000) American Psychological Association

Clifford R. Jack, Jr, MD (2012) Alzheimer Disease: New Concepts on Its Neurobiology and the Clincial Role Imaging Will Play. Radiology, 263 344-361

Lisa Mosconi (2005) Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease. European Journal of Nuclear Medicine and Molecular Imaging 32(4) 486-510

L. Wu, J Rowley, S Mohades, A Leuzy, MT Dauar, M Shin, V Fonov, J Jia, S Gauthier, P Rosa-Neto; Alzheimer’s Disease Initiative (2012) Dissociation between brain amyloid deposition and metabolism in early mild cognitive impairment. PLoS One 7(10)

Dubois et. al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ARDA criteria. The Lancet, Neurology. 2007

Unless specified by prior arrangement, the author agrees to the following terms and assurances:

  1. For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
  2. I/we further give to the following assurances
    1. I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
    2. I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
    3. To the best of my/our knowledge, all the facts in the contribution are true and accurate;
    4. The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
    5. Nothing in the contribution is obscene or libellous;
    6. Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
    7. I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).
* Works by US government employees prepared as part of official duties are in the public domain and the authors are therefore exempt from copyright assignment.